Anika Therapeutics Inc.
ANIK Healthcare Drug Manufacturers Specialty & Generic
Anika Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $112.8 million, down 5.91% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 189.3% and free cash flow grew 61.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ANIK
Anika Therapeutics Inc. (ANIK) EV/Sales
As of 16 October 2026, Anika Therapeutics Inc. (ANIK) trades at a EV/Sales of 2.1×. Over the past ten years it has ranged from 0.8× (July 2025) to 7.9× (October 2019); the current reading is higher than 21% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.9× | (47.12%) |
| FY2024 | 1.8× | (26.05%) |
| FY2023 | 2.4× | (26.14%) |
| FY2022 | 3.2× | 6.97% |
| FY2021 | 3.0× | (30.88%) |
| FY2020 | 4.4× | (11.87%) |
| FY2019 | 5.0× | 60.40% |
| FY2018 | 3.1× | (45.46%) |
| FY2017 | 5.7× | (4.06%) |
| FY2016 | 5.9× | 27.39% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | (2.88%) |
| Mar 2026 | 1.5× | 66.02% |
| Dec 2025 | 0.9× | 2.68% |
| Sep 2025 | 0.9× | (15.89%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BIOA BioAge Labs, Inc. compare | −9.7× |
| AKBA Akebia Therapeutics, Inc. compare | 0.3× |
| ACB Aurora Cannabis Inc. compare | 0.9× |
| EBS Emergent Biosolutions Inc. compare | 1.0× |
| CGC Canopy Growth Corporation compare | 1.1× |
| ANIK Anika Therapeutics Inc. | 2.1× |
| LFCR Lifecore Biomedical, Inc. compare | 3.4× |
| SIGA Siga Technologies Inc. compare | 5.0× |
| TKNO Alpha Teknova, Inc. compare | 8.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)